Report Store Get Proposal

Home Blog Oncology 17

Oncology

merck-adc-skb-phase-2-results

Others

Merck’s ADC SKB264 Shows Promising Results in Advanced Gastric Cancer: Phase 2 Data Reveals Potent Anti-Tumor Activity and Manageable Safety Profile ─ AACR 2024 (Abstract CT038)

Overexpression of TROP2 (trophoblast cell surface antigen 2) in advanced gastric cancer has been identified as a poor prognostic factor. SKB264 (MK-2870) is a TROP2 ADC (Antibody-Drug Conjugate) designed with a unique linker to attach the payload, a belotecan-derivative topoisomerase I inhibitor. This linker undergoes cleavage in response to both extracellular pH and intracellular enzymes within tumor cells, facilitating efficient release of the payload both inside tumor cells and within the tumor microenvironment, thereby exerting its anti-tumor effects. As of November 22, 2023, 48 patients with advanced gastric cancer were enrolled in a Phase 2 study evaluating S...

Explore More...

Pharma News for AbbVie, Oculis, AstraZeneca, Krystal Biotech, Alligator Biosciences

FDA Approves RINVOQ for Crohn’s Disease; FDA Approves Krystal Biotech’s Gene Therapy Vyjuvek; FDA Approves EPKINLY to Treat R/R DLBCL; FDA Orphan Drug Designation to Mitazalimab; Phase 3 Trial Result of OCS-01 Eye Drops; TAGRISSO® + Chemotherapy for the EGFR-mutated Advanced Lung Cancer

chondrosarcoma-treatment

Chondrosarcoma Treatment Market: Insight on Patient Burden and Inhibrx’s INBX-109 US Market Entry in 2026

Pharma News and Updates for Sarepta, Astellas, SiSaf, ImmPACT Bio, Otsuka, CytoAgents, Lundbeck

Sarepta Therapeutics’s SRP-9001 Gene Therapy; FDA Approves Astellas’ VEOZAH; FDA Orphan Drug Designation and Rare Pediatric Disease Designation to SiSaf’s siRNA Therapy SIS-101-ADO; FDA Grants Fast Track Designation to IMPT-314; FDA Approves First Drug for Agitation in People With Alzheimer’s Disease; FDA Accepted the CytoAgents’ IND Application for CTO1681

cancer-diagnostics-market-landscape

Cancer Diagnostic Market: Evaluating the Major Growth Factors and the Key Developments in the Domain

pharma-news-for-bms-teva-biogen-atsena-kiromic

FDA Grants Priority Review to BMS’ Luspatercept; Teva and MedinCell’s Risperidone FDA Approval; Biogens’s QALSODY FDA Accelerated Approval; FDA IND Authorization to Kiromic’s Deltacel; Atsena’s ATSN-201 FDA IND Clearance

roche-polivy-adc-for-dlbcl-treatment

Roche’s CD79b ADC POLIVY: Attempt to Change DLBCL Treatment Space

Pharma News for XORTX, Roche, Lantheus, Janssen, Daiichi Sankyo, bluebird bio, and POINT Biopharma Global

Janssen’s AKEEGA Approval; FDA Approves Roche’s Polivy Combo for Frontline B-cell Lymphoma; Daiichi Sankyo’s Quizartinib for Adults With FLT3-ITD-Positive AML; bluebird bio BLA for lovo-cel for Patients with Sickle Cell Disease; Fast Track Designation for Lu-PNT2002 for mCRPC Treatment; FDA Orphan Drug Designation to XORTX’s Oxypurinol

Pharma News and Updates for RegeneRx, Aldeyra, Oncolyze, Soligenix, Aviceda

RegeneRx’s Phase 3 Neurotrophic Keratitis Clinical Trial of RGN-259; Aldeyra’s Phase 3 INVIGORATE-2 Clinical Trial Update; FDA Orphan Drug Designation to Oncolyze’s OM-301 for Multiple Myeloma; Soligenix Provides Regulatory Update on HyBryte; FDA Fast Track Designation to SAB Biotherapeutics’s SAB-176 Influenza Immunotherapy; Aviceda IND Application for AVD-104

American Association for Cancer Research (AACR) Preview and Top Data Readouts

American Association for Cancer Research (AACR) 2023 Preview – Top Data Readouts

MedTech News for BD, Icentia, Bone Biologics, Compal Electronics, Avation Medical, Cardiovascular Systems

BD’s Advanced Ultrasound Technology for IV Insertions; Compal Electronics Launched New RFA System AblatePal; Icentia Received Clearance for CardioSTAT; Avation Medical Announced Clearance for the Vivally® System; Cardiovascular Systems’s ECLIPSE Clinical Trial; Bone Biologics Received Approval to for Pilot Trial with NB1 in Spinal Fusion Patients

Polymerase Chain Reaction Market Outlook and Forecast

Polymerase Chain Reaction (PCR) Market: Evaluating the Major Market Dynamics and Key Trends Driving the Growth

Pharma News and Updates for Cingulate, Merck, Transcenta, Ipsen, Nuance

Ipsen’s Cabometyx Rejected by NICE; Vertex and CRISPR Therapeutics’s Submit BLA to the FDA for exa-cel; Orphan Drug Designation to Osemitamab for Pancreatic Cancer; FDA Clears Keytruda/Padcev for Bladder and Urothelial Cancer; Cingulate Completes Trial of CTx-1301 for ADHD; Nuance Pharma Announces Dosing of First Patient in ENHANCE Trial

European Lung Cancer Congress 2023 Key Abstracts Analysis

European Lung Cancer Congress 2023: Key Abstracts

emerging-tlr-7-8-agonists

Role of TLR7/8 Agonists in Treating Various Cancers

Pharma News and updates for HUTCHMED, Cytokinetics, Astellas, Seagen, Nanoscope Therapeutics, Cabaletta Bio, Decibel Therapeutics

HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO

MedTech News and Updates for Mindray, Getinge, Gore, CoreLink

Mindray’s TE Air Handheld Ultrasound System; Getinge’s iCast™ Covered Stent System; Clinical Trial Update for the FLASH Proton Therapy for Cancers in the Bones; Gore’s Gore® Viafort Vascular Stent IVC Study; CoreLink’s Siber® Ti—3D Printed SI Joint Fusion System; USound and Partners’s Next-Generation Over-the-Counter Hearing Aids

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly